Anzeige
Mehr »
Login
Samstag, 18.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Paukenschlag in den USA - diese Aktien könnten profitieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QCEK | ISIN: US01626L1052 | Ticker-Symbol: 5WK
Tradegate
16.05.24
20:12 Uhr
0,595 Euro
-0,042
-6,59 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALIGOS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ALIGOS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,6100,65017.05.
0,6150,65917.05.

Aktuelle News zur ALIGOS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiAligos Therapeutics, Inc. - 8-K, Current Report1
08.05.Aligos Therapeutics reports Q1 results1
07.05.Aligos Therapeutics, Inc. - 10-Q, Quarterly Report1
07.05.Aligos Therapeutics, Inc. - 8-K, Current Report3
04.05.Aligos Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview1
30.04.Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 20241
25.04.Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study188Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting SOUTH SAN FRANCISCO, Calif., April 25...
► Artikel lesen
27.03.Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies123SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutics...
► Artikel lesen
12.03.Aligos Therapeutics Inc reports results for the quarter ended in December - Earnings Summary1
12.03.Aligos Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
12.03.Recap: Aligos Therapeutics Q4 Earnings1
12.03.Aligos Therapeutics GAAP EPS of -$0.22 beats by $0.05, revenue of $2.68M beats by $1.08M1
12.03.Aligos Therapeutics, Inc. - 10-K, Annual Report1
12.03.Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results64SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutics...
► Artikel lesen
12.03.Aligos Therapeutics, Inc. - 8-K, Current Report1
11.03.Aligos Therapeutics Earnings Preview2
05.03.Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 20243
28.02.Aligos Therapeutics, Inc. - 8-K, Current Report5
26.02.Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 20243
20.02.Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 20243
Seite:  Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1